neuropeptide Y5 receptor antagonists (RW Johnson)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameneuropeptide Y5 receptor antagonists (RW Johnson)
Drug Alias Nameneuropeptide Y5 receptor antagonists (J&J PRD)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuropeptide Y receptor type 5 antagonists
TargetsNeuropeptide Y receptor type 5
Therapy Area/IndicationsFeeding and Eating DisordersObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRW Johnson Pharmaceutical Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLCRW Johnson Pharmaceutical Research Institute
Active IndicationsN/A
Inactive IndicationsFeeding and Eating DisordersObesity

Other Information

ATC CodeN/A
Related LinksN/A